| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/22/2004 | WO2004017948A3 Use of lck inhibitor for treatment of immunologic diseases |
| 04/22/2004 | WO2004017941A3 Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist |
| 04/22/2004 | WO2004014852A3 Iminothiazolidinones as inhibitors of hcv replication |
| 04/22/2004 | WO2004011031A9 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 04/22/2004 | WO2004010945A3 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 04/22/2004 | WO2004009784A3 Novel inhibitors of kinases |
| 04/22/2004 | WO2004005544A3 Marker genes for determining renal toxicity |
| 04/22/2004 | WO2004000372A3 Disinfecting composition, cleaning tablet produced therefrom, and use thereof |
| 04/22/2004 | WO2003103770A3 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
| 04/22/2004 | WO2003101958A3 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| 04/22/2004 | WO2003097879A3 Method of identifying pancreatic ductal carcinoma-specific gene using pancreatic ductal cells, method of testing for pdc using said genes, and method of screening pharmaceutical candidate compounds for treating or preventing pdc |
| 04/22/2004 | WO2003093499A3 Therapeutic use of selective pde10 inhibitors |
| 04/22/2004 | WO2003075943A3 Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol |
| 04/22/2004 | WO2003072106A3 Use of tyrosine kinase inhibitors for treating substance use disorders |
| 04/22/2004 | WO2003070965A8 The eaat2 promoter and uses thereof |
| 04/22/2004 | WO2003051300A8 Metal complexes and formulations of rifamycin analogues and uses therof |
| 04/22/2004 | WO2003051299A8 Sulfhydryl rifamycins and uses thereof |
| 04/22/2004 | WO2003040345A3 Type 2 cytokine receptor and nucleic acids encoding same |
| 04/22/2004 | WO2003029428A8 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/22/2004 | WO2002102846A3 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state |
| 04/22/2004 | WO2002100390A3 Improved method of treating the syndrome of coronary heart disease risk factors in humans |
| 04/22/2004 | WO2002100148A3 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 04/22/2004 | WO2002098362A3 Use of rank antagonists to treat cancer |
| 04/22/2004 | WO2002092782A3 Diagnosis and treatment of malignant neoplasms |
| 04/22/2004 | WO2002090567A3 Sperm-specific cation channel, and uses therefor |
| 04/22/2004 | WO2002011711B1 Formulations of mometasone and a bronchodilator for pulmonary administration |
| 04/22/2004 | WO2001082949A9 Method of reducing side effects of chemotherapy in cancer patients |
| 04/22/2004 | WO1991007986A8 Method of treating septic shock |
| 04/22/2004 | US20040078835 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 04/22/2004 | US20040077875 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer |
| 04/22/2004 | US20040077865 Making 1-amino-6-nitroisoquinoline by reacting beta-(dimethylamino)-2-cyano-5-nitro-styrene with lithium hexamethyldisilazane or reacting said styrene compound with 2,4-dimethoxybenzylamine and then with anisole |
| 04/22/2004 | US20040077858 Making 4-(1H-indol-5-yloxy)-pyrrolo(2,1-f)(1,2,4)triazine compounds that are tyrosine kinase inhibitors; reducing vascular permeability; anticancer agents |
| 04/22/2004 | US20040077837 Microtubule-associated proteins and tubulins |
| 04/22/2004 | US20040077828 Proteins containing the motif that are capable of binding to secreted Frizzled-related protein (Sfrp) family members |
| 04/22/2004 | US20040077723 Administering mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) to treat cardiovascular disorders |
| 04/22/2004 | US20040077719 Food supplements, feed additives, dietetic, cosmetics |
| 04/22/2004 | US20040077717 Method of treating neutrophil-related diseases with topical anesthetics |
| 04/22/2004 | US20040077696 Heterocyclic inhibitors of kinases |
| 04/22/2004 | US20040077695 Anticarcinogenic, antiallergen, and antiinflammatory agents; autoimmuned diseases |
| 04/22/2004 | US20040077684 Piperidinyl compounds that selectively bind integrins |
| 04/22/2004 | US20040077680 Ureaacylated indazole, benzisoxazole, or benzisothiazole derivative with monocyte chemoattractant protein inhibitors; antiinflammatory agents; autoimmune diseases; arthritis, asthma, atherosclerosis, diabetes |
| 04/22/2004 | US20040077679 Obesity, insulin resistance, dyslipidemia; hypotensive agents; administering dopaminergic agent and agent that decreases noradrenergic neuronal activity |
| 04/22/2004 | US20040077668 Compounds, compositins, and methods |
| 04/22/2004 | US20040077657 HT3 Receptor antagonists; amyotrophic lateral sclerosis, premenstrual tension, obsessive-compulsive disorder; Parkinson*s, Alzheimer*s, and Huntington*s disease; memory, eating, psychological, and nervous system disorders |
| 04/22/2004 | US20040077638 Carboxy-substituted dibenzo(b,e)azepine derivatives; anticoagulants; wound healing, antiarthritic, hypotensive agents |
| 04/22/2004 | US20040077634 Treatment of diseases characterized by excessive or insufficient cell death |
| 04/22/2004 | US20040077624 Novel combination |
| 04/22/2004 | US20040077614 High, sustained blood concentration levels even during pregnacy without hepatic side effects; 3,17-dipropionate or dihexanoate; multiple sclerosis |
| 04/22/2004 | US20040077613 Stimulation of preadipocyte differentiation; insulin resis-tance syndrome, dyslipidemia, type 2 diabetes; LXR alpha receptor agonists |
| 04/22/2004 | US20040077611 Triple therapy of angiotensin converting enzyme inhibitor epoxy-steroidal aldosterone antagonist and diuretic or digoxin for treatment of cardiovascular disease |
| 04/22/2004 | US20040077605 Cancer, immune disorders; such as 6-hydroxy-4-methyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-(trifluoromethyl)-benzonitrile |
| 04/22/2004 | US20040077601 Methods and compositions relating to isoleucine boroproline compounds |
| 04/22/2004 | US20040077592 Cross-linked polysaccharide drug carrier |
| 04/22/2004 | US20040077591 Ameliorating physical disability in animal models; preserva-tion of body weight, reduced atrophy and weakness, extended survival |
| 04/22/2004 | US20040077587 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 04/22/2004 | US20040077561 Using 4-desacetyl-4-methylcarbonate taxol with doxorubicin; does not stimulate formation of cardiotoxic metabolic by products |
| 04/22/2004 | US20040077556 Epigallocatechin gallate, caffeine and tyrosine |
| 04/22/2004 | US20040077540 Permeabilizing peptide; reversibly enhancing paracellular transport; inhibits homotypic binding |
| 04/22/2004 | US20040077536 Human and rat pgc-3, ppar-gamma coactivations and splice variants thereof |
| 04/22/2004 | US20040077533 Methods and compositions for treating bacterial infections and diseases associated therewith |
| 04/22/2004 | US20040077525 Novel treatment |
| 04/22/2004 | US20040077523 Using matrix metalloproteinase inhibitor; preventing post-menopausal sagging |
| 04/22/2004 | US20040077051 LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications |
| 04/22/2004 | US20040077000 Using cynomologous monkey P-glycoprotein nucleic acids and polypeptides in determining bioavailability of drugs and for screening for inhibitors of cynomologous P-glycoprotein |
| 04/22/2004 | US20040076997 Determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene SEQ ID NOS:1-18 |
| 04/22/2004 | US20040076991 Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity |
| 04/22/2004 | US20040076985 Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products, useful in preventing, ameliorating, or correcting dysfunctions or diseases including HIV infection, |
| 04/22/2004 | US20040076951 Also antibodies, gene chips, transgenic non-human animals |
| 04/22/2004 | US20040076698 Drugs comprising plant extracts used for prevention amyloid formation, deposition or accumulation |
| 04/22/2004 | US20040076692 Mixtures of xanthine oxidase inhibitors and free radical scavangers, used as antiischemic agents or for prophylaxis of cardiovascular disorders |
| 04/22/2004 | US20040076688 Anti-hemorrhoid composition and process for its manufacture |
| 04/22/2004 | US20040076687 Nutritional supplement containing sea water minerals |
| 04/22/2004 | US20040076682 Novel ophthalmic compositions |
| 04/22/2004 | US20040076680 Obtained by means of physico-chemical crosslinking of the derivatives of high-molecular-weight hyaluronic acid or salts thereof; antiarthritic agents |
| 04/22/2004 | US20040076679 Gel delivery vehicles for anticellular proliferative agents |
| 04/22/2004 | US20040076672 For treating cancer and other angiogenic-dependent diseases, and more specifically, to compositions comprising anti-angiogenic factors and polymeric carriers, stents which have been coated with such compositions |
| 04/22/2004 | US20040076671 Methods and compositions for topical wound treatment |
| 04/22/2004 | US20040076664 Chewable, soft gel, high potency vitamins and method of manufacture |
| 04/22/2004 | US20040076648 Antidepressant, an n-methyl-aspartic acid receptor antagonist, a lipophilic component, water and a surfacant; oil in water emulsion |
| 04/22/2004 | US20040076628 Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 04/22/2004 | US20040076626 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| 04/22/2004 | US20040076614 For natural cellular immune defense in humans/animals; for foods/feeds |
| 04/22/2004 | US20040076608 Cytokine uses; compositions; methods |
| 04/22/2004 | US20040076601 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 04/22/2004 | DE29924609U1 Orally effective hypoglycemic compositions, useful e.g. for treating diabetes mellitus or hyperlipidemia, containing dipeptidyl peptidase IV effector and another antidiabetic agent |
| 04/22/2004 | DE10247065A1 Mixture for oral ingestion, especially as a dietetic food for treating renal insufficiency, comprises defined amounts of protein, carbohydrates and fat with a defined fatty acid composition |
| 04/22/2004 | CA2531056A1 Therapeutic combination of carnitine and antioxidant polyphenols |
| 04/22/2004 | CA2501967A1 Association between a heterocyclic compound stimulating lipid and carbohydrate metabolisms and an antioxidant agent for treating obesity |
| 04/22/2004 | CA2501964A1 Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity |
| 04/22/2004 | CA2501949A1 Implantation of encapsulated biological materials for treating diseases |
| 04/22/2004 | CA2501947A1 Azaindole derivatives as inhibitors of p38 kinase |
| 04/22/2004 | CA2501940A1 Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| 04/22/2004 | CA2501767A1 Mixture compositions for controlling ectoparasites |
| 04/22/2004 | CA2501620A1 Treatment of aml |
| 04/22/2004 | CA2501133A1 Oral formulations for proteins and polypeptides |
| 04/22/2004 | CA2500742A1 Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis |
| 04/22/2004 | CA2499682A1 Epo d + 5-fu/gemcitabine |
| 04/22/2004 | CA2482013A1 Process for preparing tannate tablet capsule or other solid dosage forms |
| 04/21/2004 | EP1411124A2 Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same |
| 04/21/2004 | EP1411056A2 Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for their preparation |